Curocell

Curocell Current Liabilities

The Current Liabilities of Curocell (372320.KQ) as of Oct 27, 2026 is 890.00 KRW. In the previous year, Current Liabilities was 36.01 B KRW — a change of -100.00% (lower).

Current Liabilities

890.00KRW

YoY

-100.00%

Last updated:

Current Liabilities of Curocell is 2025 890.00 KRW. Current Liabilities of Curocell was 2024 36.01 B KRW. It decreases by -100.00% lower compared to the previous year.

The Curocell Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2021
614.37 M KRW
Jan 1, 2022
713.75 M KRW
Jan 1, 2023
1.56 B KRW
Jan 1, 2024
36.01 B KRW
Jan 1, 2025
890.00 KRW
The Curocell Current Liabilities history
YEARCurrent LiabilitiesYoY
890.00KRW-100.00%
36.01 BKRW+2,213.06%
1.56 BKRW+118.14%
713.75 MKRW+16.18%
614.37 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curocell Stock analysis

What does Curocell do? Curocell Inc makes money through the development and commercialization of CAR-T therapy technologies for cancer treatment. The company focuses on novel chimeric antigen receptor (CAR)-T therapies targeting specific cancer antigens, improving medicinal effects, reducing side effects, and automating quality analysis. These products are developed for pharmaceutical companies and healthcare providers seeking advanced cancer treatments. The firm's R&D efforts target the biotechnology sector, specifically oncology applications. Curocell Inc's business model centers on creating innovative CAR-T therapies that address unmet medical needs in cancer care. The company's research and development activities are directed at enhancing the efficacy and safety of CAR-T treatments, which are sold to pharmaceutical firms for further development and distribution. The firm's products are positioned within the biotechnology industry, catering to the growing demand for targeted cancer therapies. The company's revenue streams come from the sale of its developed CAR-T technologies to pharmaceutical partners. These partnerships enable the commercialization of Curocell's innovations in the global oncology market. Curocell Inc operates within the biotechnology sector, specifically focusing on the development of next-generation CAR-T therapies for cancer patients. Curocell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curocell stock

Current Liabilities of Curocell is 890.00 KRW in 2025.

Current Liabilities of Curocell changed from 36.01 B KRW to 890.00 KRW, representing a -100.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Curocell since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Curocell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Curocell

All Key Metrics — Curocell